Amarin Corporation PLC (NASDAQ:AMRN) Analyst Rating Consensus

Amarin Corporation PLC (NASDAQ:AMRN) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1 by 3 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys.

Other Equity analysts have also commented on the company shares. Jefferies initiates coverage on Amarin Corporation PLC (NASDAQ:AMRN) In a research note issued to the investors, the brokerage major announces price-target of $3.5 per share.The shares have been rated Buy. The rating by the firm was issued on May 12, 2016.

Amarin Corporation PLC (NASDAQ:AMRN): The mean estimate for the short term price target for Amarin Corporation PLC (NASDAQ:AMRN) stands at $6.5 according to 3 Analysts. The higher price target estimate for the stock has been calculated at $10 while the lower price target estimate is at $4.

Amarin Corporation PLC (NASDAQ:AMRN) witnessed a decline in the market cap on Tuesday as its shares dropped 2.38% or 0.05 points. After the session commenced at $2.08, the stock reached the higher end at $2.11 while it hit a low of $2.02. With the volume soaring to 879,528 shares, the last trade was called at $2.05. The company has a 52-week high of $2.65. The company has a market cap of $380 million and there are 185,124,340 shares in outstanding. The 52-week low of the share price is $1.24.

Amarin Corporation plc has dropped 3.3% in the last five trading days, however, the shares have posted positive gains of 19.19% in the last 4 weeks. Amarin Corporation plc is up 35.76% in the last 3-month period. Year-to-Date the stock performance stands at 8.47%.

Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarins lead product, Vascepa (icosapent ethyl) capsules, are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia. The Company sells Vascepa principally to various wholesalers, as well as regional wholesalers and specialty pharmacy providers, who in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Vascepa is available in the United States by prescription only. Amarin is also developing Vascepa for the treatment of patients with high (TG over 200 milligrams per deciliter and less than 500 milligrams per deciliter) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.